Neutrogena Ultra Sheer Body Mist Sunscreen Broad Spectrum Spf 30 shortage — US supply status & alternatives

Neutrogena Ultra Sheer Body Mist Sunscreen Broad Spectrum Spf 30

—

In supply · Australia

Neutrogena Ultra Sheer body mist sunscreen BROAD SPECTRUM SPF 30, Avobenzone , Homosalate

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes

Active ingredient (INN)	Neutrogena Ultra Sheer Body Mist Sunscreen Broad Spectrum Spf 30
Brand names	Neutrogena Ultra Sheer body mist sunscreen BROAD SPECTRUM SPF 30, Avobenzone , Homosalate
Therapeutic category	Auto-created by FDA MedWatch — Drug Safety Alerts scraper
Controlled substance	No
Marketing-authorisation holders	Kenvue Brands LLC
Registrations on file	1
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders1 registration · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
Neutrogena Ultra Sheer Body Mist Sunscreen Broad Spectrum SPF 30	30; 80; 50; 80mg/g; mg/g; mg/g; mg/g	spray	🇺🇸 US	Kenvue Brands LLC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.